GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Remdesivir (Veklury, adults)

Local official-label summaryBase record retrieved 2026-09-05See the evidence for this drug3 sources available - open source summaries, references and comparisons

Veklury

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (3)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

Remdesivir (Veklury, adults) - selected U.S. labeling

Product / population
Adult COVID-19 treatment with intravenous remdesivir. Pediatric weight-based dosing is excluded.
Renal measure
All degrees of renal impairment; no renal dose reduction in selected labeling.
Labeled basic dosing

Give 200 mg IV on day 1, then 100 mg IV once daily from day 2. Infuse over 30-120 minutes. Course duration depends on hospitalization and disease severity.

Renal information and dialysis

The selected label recommends no change at any degree of renal impairment, including dialysis. Dosing need not be timed around dialysis.

Selected warnings and limits

Check hepatic laboratory tests and prothrombin time before treatment and as appropriate during therapy. Infusion reactions require access to emergency treatment.

Source revision: Label revision date not separately recorded; retrieval date is not the revision date. | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0978fa8-53ff-4ca2-82a7-567fd3e958ca

Scope: Selected dosing/renal sections read; concise local summary, not full prescribing information. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Official product label

Remdesivir (Veklury, adults) - selected U.S. labeling

Adult COVID-19 treatment with intravenous remdesivir. Pediatric weight-based dosing is excluded.

Renal method: All degrees of renal impairment; no renal dose reduction in selected labeling.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - Veklury

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

IV VEKLURY; selected renal and dialysis instructions, adult record.

Renal method: Any degree of renal impairment, including dialysis.
Retrieved: 2026-09-07

Read local renal resultOpen original reference
Professional guidance

UCSF remdesivir - renal and dialysis protocols

Adult COVID-19 treatment with intravenous remdesivir. Pediatric weight-based dosing is excluded.

Renal method: CrCl mL/min; IHD and continuous hemodialysis
Retrieved: 2026-09-05

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeRemdesivir (Veklury, adults) - selected U.S. labelingGlobalRPh RX List - VekluryUCSF remdesivir - renal and dialysis protocols
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0978fa8-53ff-4ca2-82a7-567fd3e958ca

Product and population scope

Adult COVID-19 treatment with intravenous remdesivir. Pediatric weight-based dosing is excluded.

RDM31-remdesivir-scope · Source section: Editorial scope tied to selected U.S. labelRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Remdesivir (Veklury, adults) - selected U.S. labeling

Open original reference

Open / share this exact local source

U.S. product labeling / DailyMed · Adult COVID-19 treatment with intravenous remdesivir. Pediatric weight-based dosing is excluded.

Renal method: All degrees of renal impairment; no renal dose reduction in selected labeling.
Source date: Label revision date not separately recorded; retrieval date is not the revision date.
Retrieved: 2026-09-05

Selected dosing/renal sections read; concise local summary, not full prescribing information.

Labeled basic dosing

Give 200 mg IV on day 1, then 100 mg IV once daily from day 2. Infuse over 30-120 minutes. Course duration depends on hospitalization and disease severity.

RDM31-remdesivir-label-dose · Source locator: 2.3, 2.5

Renal information and dialysis

The selected label recommends no change at any degree of renal impairment, including dialysis. Dosing need not be timed around dialysis.

RDM31-remdesivir-label-renal · Source locator: 2.4; 8.6

Selected warnings and limits

Check hepatic laboratory tests and prothrombin time before treatment and as appropriate during therapy. Infusion reactions require access to emergency treatment.

RDM31-remdesivir-label-limits · Source locator: 2.1, 2.2; 5.1, 5.2

Source identity and provenance
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0978fa8-53ff-4ca2-82a7-567fd3e958ca
Retrieved
2026-09-05
DailyMed Set ID
c0978fa8-53ff-4ca2-82a7-567fd3e958ca
Renal-function method
All degrees of renal impairment; no renal dose reduction in selected labeling.
Source date/version
Label revision date not separately recorded; retrieval date is not the revision date.
Hash meaning
SHA-256 identifies this local summary, not original SPL XML or label PDF.
Local summary SHA-256
a311926a1780750c078793b556b7490624d028d14e671f3ac4c15ebb5bec4e77
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - Veklury

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · IV VEKLURY; selected renal and dialysis instructions, adult record.

Renal method: Any degree of renal impairment, including dialysis.
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

The retrieved source recommends no dose adjustment for any degree of renal impairment, including dialysis, and permits administration without regard to dialysis timing. This statement does not replace the age/weight, indication, duration, hepatic monitoring or other product instructions. Pediatric severe-renal data limitations in the source should not be filled by applying adult doses. Increased metabolite or excipient exposure is not itself converted into an unsupported reduced regimen.

RDM40-rxlist-remdesivir-10f0a16d53-C1 · Source locator: Selected renal dosing, renal impairment, toxicity and pharmacokinetic subsections as identified in the summary.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/veklury-drug/
Retrieved
2026-09-07
Renal-function method
Any degree of renal impairment, including dialysis.
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
3f41325babb14e3596358fb7a8418a1773af44078772dfd8814cf6ff33e08ca7
Separate professional-source layer

University and professional protocols

Professional

UCSF remdesivir - renal and dialysis protocols

Open original reference

Open / share this exact local source

University of California San Francisco (UCSF) · Adult COVID-19 treatment with intravenous remdesivir. Pediatric weight-based dosing is excluded.

Renal method: CrCl mL/min; IHD and continuous hemodialysis
Source date: Revision date not stated on the reviewed page.
Retrieved: 2026-09-05

Separate professional-source protocol; not automatically equivalent to product labeling.

Source-specific renal protocol

UCSF gives 200 mg IV once, then 100 mg every 24 hours for both renal-function columns and for intermittent/continuous hemodialysis. Its CrCl-below-30 column adds a vehicle-accumulation risk/benefit caution without reducing the dose.

RDM31-remdesivir-prof-1 · Source locator: Adult non-dialysis and intermittent/continuous hemodialysis tables

Source-specific limits

The printed non-dialysis headings use >30 and <30, omitting exact 30. The selected U.S. label explicitly permits the same dosing at all renal-function levels. Do not treat the institutional vehicle note as a labeled contraindication.

Source identity and provenance
Source
https://idmp.ucsf.edu/content/remdesivir-0
Retrieved
2026-09-05
Renal-function method
CrCl mL/min; IHD and continuous hemodialysis
Source date/version
Revision date not stated on the reviewed page.
Hash meaning
SHA-256 identifies the local paraphrase, not original source bytes.
Local summary SHA-256
61e446f231d9dd7e348ae0f9ce2c382037f4ea0a461470171dfc403a14fe2838

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 1 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0978fa8-53ff-4ca2-82a7-567fd3e958ca
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
multisource addition
Local text SHA-256
c7715868c1a95df51a6a6ae2dff44c44108849bc6c8edcc22a175b5e9adae1c2
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report